Galactus Bioengineering and Biolistics (GBB) is an ag-tech whose mission is to create new drugs derived from gene edited, medical plant species. Gene edits are made in medical plants to increase clinical efficacy, optimize safety profile, and maximize yield of selected bioactive compounds. Compounds derived from these novel medical plants will then undergo preclinical and, multicenter, clinical studies to obtain FDA and EMA approval.

The primary active ingredient in the majority (>80-90%) of cosmetics and nutraceutical products are plant derived, and an estimated over 40% of pharmaceutical medications are also plant derived. Despite this, advanced genetic modifications in plants for pharmaceutical applications remain largely unexplored. Although widely used in large scale production of several staple food crops since the 90’s, the pharmaceutical industry has yet to fully benefit from the application of these technologies.

Galactus Bio’s ag-tech pharmaceutical pipeline will enable:

– Creation of new, patent protected, gene edited plants for both in-house projects and outside clients every 6- 12 months

– Genetically optimized yield and clinical efficacy of medicinal plants

– Pharmaceutical product and manufacturing IP extending all the way back to the proprietary, gene edited plant species

– Strong patent protection facilitated by unique DNA barcoding

Galactus Bio is a Harvard spin out ag-tech with offices in Boston, MA, USA; Tuzla, Bosnia, and Skopje, Macedonia.

For more information contact: info@galactusbio.com